768 related articles for article (PubMed ID: 19799473)
1. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.
Liu Z; Doan QV; Malin J; Leonard R
Appl Health Econ Health Policy; 2009; 7(3):193-205. PubMed ID: 19799473
[TBL] [Abstract][Full Text] [Related]
2. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
Sehouli J; Goertz A; Steinle T; Dubois R; Plesnila-Frank C; Lalla A; von Minckwitz G
Dtsch Med Wochenschr; 2010 Mar; 135(9):385-9. PubMed ID: 20180162
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
Lyman G; Lalla A; Barron R; Dubois RW
Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
Ramsey SD; Liu Z; Boer R; Sullivan SD; Malin J; Doan QV; Dubois RW; Lyman GH
Value Health; 2009; 12(2):217-25. PubMed ID: 18673353
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
Lyman GH; Lalla A; Barron RL; Dubois RW
Clin Ther; 2009 May; 31(5):1092-104. PubMed ID: 19539110
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients.
Danova M; Chiroli S; Rosti G; Doan QV
Tumori; 2009; 95(2):219-26. PubMed ID: 19579869
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.
Whyte S; Cooper KL; Stevenson MD; Madan J; Akehurst R
Value Health; 2011 Jun; 14(4):465-74. PubMed ID: 21669371
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
Fust K; Li X; Maschio M; Barron R; Weinstein MC; Parthan A; Walli-Attaei M; Chandler DB; Lyman GH
Gynecol Oncol; 2014 Jun; 133(3):446-53. PubMed ID: 24657302
[TBL] [Abstract][Full Text] [Related]
10. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
Naeim A; Henk HJ; Becker L; Chia V; Badre S; Li X; Deeter R
BMC Cancer; 2013 Jan; 13():11. PubMed ID: 23298389
[TBL] [Abstract][Full Text] [Related]
11. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
Hill G; Barron R; Fust K; Skornicki ME; Taylor DC; Weinstein MC; Lyman GH
J Med Econ; 2014 Jan; 17(1):32-42. PubMed ID: 24028444
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.
Gebremariam GT; Fentie AM; Beyene K; Sander B; Gebretekle GB
BMC Health Serv Res; 2022 Dec; 22(1):1600. PubMed ID: 36585648
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer.
Aapro MS; Chaplin S; Cornes P; Howe S; Link H; Koptelova N; Mehl A; Di Palma M; Schroader BK; Terkola R
Support Care Cancer; 2023 Sep; 31(10):581. PubMed ID: 37728795
[TBL] [Abstract][Full Text] [Related]
15. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.
Morrison VA; Wong M; Hershman D; Campos LT; Ding B; Malin J
J Manag Care Pharm; 2007 May; 13(4):337-48. PubMed ID: 17506600
[TBL] [Abstract][Full Text] [Related]
16. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
17. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma--a cost-effectiveness analysis.
Numnum TM; Kimball KJ; Rocconi RP; Kilgore LC; Straughn JM
Int J Gynecol Cancer; 2007; 17(5):1019-24. PubMed ID: 17386043
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
[TBL] [Abstract][Full Text] [Related]
19. [Cost-effectiveness of primary prophylaxis with PEG-rhG-CSF in early-stage breast cancer patients receiving chemotherapy in China].
Xia W; Wang SS; Hu H; Zhao FL; Xu F; Hong RX; Jiang KK; Yuan ZY; Shi YX; Zhao K; Huang JJ; Xue C; Bi XW; Lu QY; An X; Zhang JM
Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):861-867. PubMed ID: 33113628
[No Abstract] [Full Text] [Related]
20. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
Wolowacz SE; Cameron DA; Tate HC; Bagust A
J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
